Follicular lymphoma · 12 regimens
Cost vs Efficacy · 6 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bevacizumab and Rituximab Variant #01 | — | R 244 016 | 84d | ~20.7 mo | — | ~4 | ~R 550 716 PFS proxy · indirect | 1 |
Obinutuzumab monotherapy Variant #06 | — | R 190 790 | 21d | — | — | ~7 | ~R 476 974 indirect | — |
Zanubrutinib and Obinutuzumab (ZO) Variant #01 | — | R 184 994 | 28d | — | — | ~30 | ~R 2 449 478 indirect | — |
Lenalidomide and Rituximab (R2) Variant #08 | — | R 134 502 | 28d | ~26.7 mo | — | ~11 | ~R 396 684 PFS proxy · indirect | 4 |
Copanlisib and Rituximab Variant #01 Partial | — | R 129 524 | 28d | ~21.5 mo | — | ~10 | ~R 207 238 PFS proxy · indirect | 1 |
R-FCM Variant #01 | — | R 67 954 | 28d | — | — | ~6 | ~R 252 295 indirect | — |
Bortezomib and Rituximab (VR) Variant #01 | — | R 58 571 | 60d | ~12.8 mo | — | ~5 | ~R 241 048 PFS proxy · indirect | 1 |
Bendamustine and Rituximab (BR) Variant #01 | — | R 33 874 | 28d | — | — | ~8 | ~R 270 994 PFS proxy · indirect | 1 |
R-CHOP Variant #08 | — | R 26 946 | 21d | ~44.4 mo | — | ~9 | ~R 242 515 PFS proxy · indirect | 3 |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | ~30.8 mo | — | ~24 | ~R 52 272 PFS proxy · indirect | 2 |
Ibritumomab tiuxetan protocol Variant #18 Partial | — | — | 8d | ~36.5 mo | — | ~1 | — | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~11.0 mo | — | ~1 | — | 6 |
12 of 12 regimens shown